Medicine and Dentistry
Inflammatory Bowel Disease
100%
Pediatrics
89%
Ulcerative Colitis
38%
Crohn's Disease
34%
Patient with Inflammatory Bowel Disease
25%
Diseases
22%
COVID-19 Vaccination
21%
Tumor Necrosis Factor
19%
Severe Acute Respiratory Syndrome Coronavirus 2
18%
COVID-19
17%
Humoral Immunity
16%
Odds Ratio
13%
Pediatric Gastroenterology
12%
Pediatric Surgery
12%
Cohort Analysis
10%
Retrospective Cohort Study
10%
Quality of Life
10%
Mesalazine
10%
Adverse Event
9%
Infection
9%
Colitis
8%
Disease Course
8%
Disease Activity
8%
Prevalence
7%
Pediatrics Patient
7%
Necrosis
7%
Program Director
7%
Surgeon
7%
Gastrointestinal Surgery
6%
Biological Therapy
6%
Child Health
5%
Patient-Reported Outcome
5%
Outcome Assessment
5%
Somatomedin C
5%
Liver Disease
5%
Gastroesophageal Reflux
5%
Body Mass Index
5%
Clinical Trial
5%
Needs Assessment
5%
Blood Proteins
5%
Upadacitinib
5%
Solid Organ Transplantation
5%
HLA DQA1 Antigen
5%
Diagnostic Delay
5%
Drug Antibody
5%
Clinician
5%
Keyphrases
Inflammatory Bowel Disease
80%
Ulcerative Colitis
30%
Pediatric Inflammatory Bowel Disease
29%
Pediatric
25%
Crohn's Disease
22%
Pediatric Crohn's Disease
20%
Anti-tumor Necrosis Factor (anti-TNF)
19%
Enhanced Recovery Program
17%
Very Early-onset Inflammatory Bowel Disease
17%
Humoral Immune Response
16%
Laboratory Evaluation
15%
SARS-CoV-2 Vaccination
15%
North America
15%
Severe Acute Respiratory Syndrome coronavirus-2 Vaccine
13%
Odds Ratio
13%
Protocol Implementation
11%
Adverse Events
11%
Adalimumab
11%
Pediatric Surgery
11%
COVID-19
10%
Inception Cohort Study
10%
Monotherapy
9%
Confidence Interval
9%
Infliximab
9%
Treatment Failure
8%
Antibody Level
8%
Mesalazine
8%
Anti-tumor Necrosis Factor Therapy
8%
Disease Activity
8%
Invasive Testing
8%
CBir1
7%
Methotrexate
7%
Paediatric Gastroenterology
7%
Children's Health
7%
Program Directors
7%
Pediatric Gastroenterology Fellowship
7%
Pediatric Ulcerative Colitis
7%
Vaccination
7%
Newly Diagnosed
6%
Corticosteroid-Free Remission
6%
Anti-drug Antibodies
6%
Pediatric Patients
6%
Retrospective Cohort Study
6%
Clinical Response
6%
Anti-TNF Treatment
6%
Pragmatic Trial
6%
Response Predictors
6%
Colitis Therapy
6%
Antibody Development
6%
Biologic Therapy
5%